As lobbyists purporting to represent doctors and hospitals fight attempts to control surprise medical bills, it has become increasingly clear that the force behind the effort is not just medical professionals, but also investors from private equity firms.
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
The Wednesday night event marked the second night in a row for Democratic presidential hopefuls to stake claims on how to fix the health care system.
Hay casi tantas versiones de “Medicare para Todos” como candidatos demócratas, y cada uno piensa que su plan es el camino para asegurar a todos los estadounidenses.
Candidates used their varying views on how to achieve universal coverage — whether through Medicare for All or more incremental steps — as a means to differentiate themselves from the field.
Asked to choose between building on the Affordable Care Act and replacing it with a national Medicare for All plan, 55% of Democrats and Democratic-leaning independents said they would expand the existing law, according to a Kaiser Family Foundation poll released Tuesday.
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
Efforts to control drug prices seemed on a glide path earlier this year after gaining traction at the White House and in Congress. But prospects today look less certain and highly controversial.
A draft plan spearheaded by House Speaker Nancy Pelosi would allow the federal government for the first time to negotiate prices for 250 drugs for Medicare and apply those prices to all payers, including employers and insurers.
Despite what New York Mayor Bill de Blasio claimed during the first night of the presidential debates, universal health care in the Big Apple is still in the seeding stage.